PF-429242

PF-429242 is a **small molecule inhibitor** that selectively targets **site-1 protease (S1P, also called subtilisin/kexin-isozyme 1, SKI-1)**, an essential enzyme involved in the activation of sterol regulatory element-binding proteins (SREBPs), thereby regulating lipid and cholesterol homeostasis in cells. It is primarily investigated for its **anticancer activity**, notably in renal cell carcinoma (RCC), where it inhibits cell proliferation, induces apoptosis, and provokes cell cycle arrest by blocking the SREBP1-S1P signaling cascade[5][2]. Additionally, PF-429242 has notable **antileishmanial activity**: it disrupts parasite morphology and mitochondrial integrity, induces autophagy, and stimulates host immune responses such as increased nitric oxide (NO) and tumor necrosis factor (TNF) production, without activating reactive oxygen species (ROS) or IL-10 pathways[1][3]. The compound has also shown potential synergy when combined with chloroquine in hepatocellular carcinoma (HCC) cells, leading to novel pH-dependent cell death mechanisms that bypass autophagy-related drug resistance[4].